Table 4.

Clinical performance of p16/Ki-67 in a colposcopy population

SensitivitySpecificityPPVNPVReferral
All women CIN2+ (n = 258)86.4% (81.5–90.2)59.5% (54.2–64.5)60.1% (54.9–65.1)86.1% (81.1–90.0)59.55% (55.7–63.3)
All women CIN3+ (n = 89)93.2% (85.3–97.2)46.1% (41.8–50.4)22.3% (18.3–27.0)97.6% (94.6–99.0)
<30 y and CIN2+ (n = 190)86.8% (81.0–91.1)55.4% (48.9–61.7)60.4% (54.3–66.2)84.3% (77.5–89.4)63.19% (58.4–67.6)
<30 y and CIN3+ (n = 52)90.4% (78.2–96.4)40.5% (35.6–45.7)17.2% (13.0–22.3)96.9% (92.4–98.8)
≥30 y and CIN2+ (n = 66)84.8% (73.4–92.1)67.5% (58.3–75.6)58.9% (48.3–68.8)89.0% (80.3–94.3)51.08% (44.0–58.2)
≥30 y and CIN3+ (n = 36)97.2% (83.8–99.9)60.0% (51.7–67.8)36.8% (27.4–47.4)98.9% (93.2–99.9)